These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
184 related items for PubMed ID: 17011868
1. Progression of choroidal neovascularization following injection of pegaptanib sodium (macugen) in two eyes with neovascular age-related macular degeneration. Williams AJ, Fekrat S. Am J Ophthalmol; 2006 Oct; 142(4):683-4. PubMed ID: 17011868 [Abstract] [Full Text] [Related]
2. [Clinical experience in the treatment of neovascular age-related macular degeneration with pegaptanib]. Maier M, Feucht N, Huebner M, Lohmann C. Klin Monbl Augenheilkd; 2008 Jun; 225(6):582-7. PubMed ID: 18516780 [Abstract] [Full Text] [Related]
3. Treatment of naïve lesions in neovascular age-related macular degeneration with pegaptanib. Quiram PA, Hassan TS, Williams GA. Retina; 2007 Sep; 27(7):851-6. PubMed ID: 17891008 [Abstract] [Full Text] [Related]
4. RPE tears after pegaptanib treatment in age-related macular degeneration. Chang LK, Flaxel CJ, Lauer AK, Sarraf D. Retina; 2007 Sep; 27(7):857-63. PubMed ID: 17891009 [Abstract] [Full Text] [Related]
5. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration. Sawada O, Miyake T, Kakinoki M, Sawada T, Kawamura H, Ohji M. Retina; 2010 Sep; 30(7):1034-8. PubMed ID: 20616682 [Abstract] [Full Text] [Related]
6. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF, Fromow-Guerra J, Sanchez JG, Maia M, Berrocal MH, Wu L, Saravia MJ, Costa RA, Pan-American Collaborative Retina Study Group. Retina; 2008 Sep; 28(10):1387-94. PubMed ID: 18827735 [Abstract] [Full Text] [Related]
7. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial GroupDepartment of Ophthalmology, Harvard Medical School, Retina Service, Massachusetts Eye and Ear Infirmary, 243 Charles Street, Boston, MA 02114, USA. djdamico@meei.harvard.edu, D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET, Guyer DR, Katz B. Ophthalmology; 2006 Jun; 113(6):992-1001.e6. PubMed ID: 16647134 [Abstract] [Full Text] [Related]
8. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Arevalo JF, Sánchez JG, Wu L, Berrocal MH, Alezzandrini AA, Restrepo N, Maia M, Farah ME, Brito M, Díaz-Llopis M, Rodríguez FJ, Reategui G, Iturralde-Iraola J, Udaondo-Mirete P, Pan-American Collaborative Retina Study Group. Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989 [Abstract] [Full Text] [Related]
9. [Pegaptanib sodium one-year treatment study for neovascular age-related macular degeneration]. Tano Y, Pegaptanib Sodium Multi-center Study Group. Nippon Ganka Gakkai Zasshi; 2008 Jul; 112(7):590-600. PubMed ID: 18702350 [Abstract] [Full Text] [Related]
10. Pegaptanib: choroidal neovascularization in patients with age-related macular degeneration and previous arterial thromboembolic events. Battaglia Parodi M, Di Bartolo E, Brue C, Cappello E, Furino C, Giuffrida S, Imparato M, Reibaldi M. Eur J Ophthalmol; 2018 Jan; 28(1):58-62. PubMed ID: 29077191 [Abstract] [Full Text] [Related]